西安环球印务股份有限公司2023年度财务决算报告 西安环球印务股份有限公司 2023 年度财务决算报告 2023 年，公司管理层在董事会的坚强领导下，全面落实"两新两运营 高质 量发展"的工作思路，带领全体员工齐心协力抓经营，2023 年主业医药包装板 块主要经营指标均按年初目标任务完成，但互联网数字营销业务受外部经济环境 及国家政策影响，主要指标较上年同期有不同程度的下降。 希格玛会计师事务所（特殊普通合伙）已对公司本年度的财务报表进行了审 计，认为本公司的会计报表已经按照企业会计准则和《企业会计制度》的规定编 制，在所有重大方面公允地反映了公司 2023 年 12 月 31 日的财务状况以及 2023 年度经营成果和现金流量，并为本公司 2023 年度会计报表出具了无解释性说明 的标准无保留意见的审计报告。审计后的决算情况如下： 一、财务报表合并范围 截至 2023 年 12 月 31 日，公司财务报表合并范围内子公司包括： 二、报告期内主要合并财务数据及指标 单位：万元 | 项 目 | 2023 年度/2023 | 2022 年度/2022 | 增减额 | 增减率 | | --- | --- | --- ...

Financial Performance - The company's revenue for Q1 2023 was ¥404,959,881.53, a decrease of 24.95% compared to ¥539,587,507.41 in the same period last year[4] - Net profit attributable to shareholders was ¥28,729,049.41, representing an increase of 4.84% from ¥27,402,907.36 year-on-year[4] - The company's net profit for Q1 2023 was not explicitly stated, but the significant decrease in revenue and costs indicates a challenging financial environment[22] - The net profit for Q1 2023 was CNY 32,498,774.16, an increase of 1.79% compared to CNY 31,925,678.59 in Q1 2022[24] - The operating profit for the quarter was CNY 36,058,491.19, slightly up from CNY 35,695,830.95 in the same period last year[24] - The total profit amounted to CNY 35,958,491.19, compared to CNY 35,695,830.96 in Q1 2022, reflecting a growth of 0.74%[24] Cash Flow and Liquidity - The net cash flow from operating activities was -¥10,698,900.14, a decline of 141.46% compared to ¥25,807,505.26 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY -10,698,900.14, a significant decrease from a net inflow of CNY 25,807,505.26 in Q1 2022[27] - Cash flow from investing activities resulted in a net outflow of CNY -73,779,314.12, compared to CNY -7,366,367.50 in the same quarter last year[28] - Cash flow from financing activities recorded a net outflow of CNY -119,900,261.61, worsening from CNY -61,006,303.84 in Q1 2022[28] - Cash and cash equivalents at the end of the reporting period amount to RMB 711,217,748.73, down from RMB 906,522,100.48 at the beginning of the year[19] - The total cash and cash equivalents at the end of the quarter were CNY 682,889,219.70, down from CNY 233,565,112.62 at the end of Q1 2022[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,483,533,511.47, down 4.46% from ¥2,599,603,496.21 at the end of the previous year[4] - Accounts receivable increased to CNY 541,890,087.14 from CNY 446,449,714.46, reflecting a rise of approximately 21%[21] - Total liabilities decreased to CNY 771,114,976.93 from CNY 919,683,735.82, a reduction of about 16%[21] - Inventory decreased by 47.77% to ¥49,875,558.27, attributed to increased sales and reduced stocking[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,804[12] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds 36.42% of shares, totaling 116,550,000 shares[12] Investments and Projects - Cash paid for fixed asset purchases surged by 742.03% to ¥65,552,148.76, reflecting significant investments in key production equipment[10] - The company is constructing a green packaging smart manufacturing industrial park, which includes primary and secondary pharmaceutical packaging production centers and a technology R&D center[16] - The registered capital for the new materials project company in Tianjin is not less than RMB 80 million, with a total investment of at least RMB 100 million[17] Tax and Expenses - The company’s tax expenses increased by 64.99% to ¥3,118,220.95 due to higher VAT payments[10] - Research and development expenses for Q1 2023 were CNY 14,132,285.59, down from CNY 16,502,638.89, a decrease of approximately 13%[22] Future Outlook - The company plans to focus on market expansion and new product development to enhance future growth prospects[22]

Financial Performance - The company's revenue for Q3 2022 was ¥396,076,142.24, a decrease of 41.99% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥22,782,631.86, down 3.99% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥19,391,107.03, a decline of 7.14% compared to the previous year[4] - Total operating revenue for Q3 2022 was ¥1,401,026,910.63, a decrease of 39.2% compared to ¥2,307,918,790.20 in the same period last year[20] - Net profit for Q3 2022 was ¥95,883,296.21, a decline of 19.2% from ¥118,749,758.29 in Q3 2021[21] - The basic earnings per share for Q3 2022 were ¥0.09, a decrease of 18.18% compared to the same period last year[4] - Earnings per share for Q3 2022 was ¥0.33, compared to ¥0.40 in the same quarter last year[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,830,833,597.44, an increase of 11.80% from the end of the previous year[4] - The company's total assets amounted to approximately CNY 1.83 billion, an increase from CNY 1.64 billion at the beginning of the year[18] - The company's total liabilities increased to ¥894,921,659.65 from ¥793,088,893.48 year-on-year, reflecting a rise of 12.8%[20] - The total equity attributable to shareholders of the parent company rose to ¥841,393,967.60, up from ¥758,397,541.67, indicating an increase of 10.9%[20] Cash Flow - The company reported a net cash flow from operating activities of ¥54,425,322.06, which increased by 17.95% year-to-date[4] - The net cash flow from operating activities for Q3 2022 was ¥54,425,322.06, an increase from ¥46,144,103.80 in Q3 2021, reflecting a growth of approximately 17.8%[23] - Cash flow from operating activities for the current period was ¥2,671,883,867.58, slightly up from ¥2,650,294,570.86 in the previous year[22] - The ending balance of cash and cash equivalents was ¥226,962,636.58, down from ¥257,048,284.26 in the previous year, a decrease of about 11.7%[23] - Cash inflow from financing activities amounted to ¥460,134,408.71, up from ¥360,447,362.99 in Q3 2021, representing an increase of approximately 27.7%[23] - The net cash flow from financing activities was negative at -¥53,296,378.38, contrasting with a positive net cash flow of ¥16,322,547.83 in Q3 2021[23] Investments and Projects - The company is currently constructing a green packaging intelligent manufacturing industrial park in Xi'an, which includes primary and secondary pharmaceutical packaging production centers and a technology R&D center[11] - The company signed a total contracting agreement for the construction project with China Construction Fourth Engineering Bureau[11] - The company received government subsidies amounting to ¥4,745,378.24 during the reporting period, contributing to its non-recurring gains[5] - The company plans to issue up to 68,040,000 A-shares through a private placement, which would account for no more than 27% of the total share capital before the issuance[12] Changes in Financial Metrics - The company's cash and cash equivalents decreased to CNY 241.23 million from CNY 299.36 million at the beginning of the year, reflecting a decline of approximately 19.4%[18] - Accounts receivable stood at CNY 272.46 million, slightly down from CNY 284.45 million, indicating a decrease of about 4.2%[18] - The company reported a significant increase in prepayments, which rose to CNY 436.81 million from CNY 154.37 million, marking an increase of approximately 183.5%[18] - The company’s inventory decreased to CNY 55.83 million from CNY 114.56 million, a decline of about 51.2%[18] - The company’s long-term equity investments increased to CNY 124.60 million from CNY 122.02 million, showing a growth of approximately 2.1%[18] - The company’s fixed assets increased to CNY 272.04 million from CNY 257.12 million, reflecting an increase of about 5.8%[18] Shareholder Actions - The company’s major shareholder, Hong Kong Yuanshi International Co., Ltd., plans to reduce its holdings by up to 15,120,000 shares, representing 6% of the total share capital[15]

中信证券股份有限公司关于 西安环球印务股份有限公司 部分募投项目延期的核查意见 中信证券股份有限公司（以下简称中信证券或保荐人）作为西安环球印务股 份有限公司（以下简称环球印务或公司）非公开发行股票的保荐人，根据《证券 发行上市保荐业务管理办法》《深圳证券交易所股票上市规则》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求》等有关法律法规的要求， 对公司部分募投项目延期事项进行了审慎核查。核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准西安环球印务股份有限公司非公开发 行股票的批复》（证监许可〔2022〕397 号）核准，公司向特定对象非公开发行人 民币普通股 68,040,000 股，每股面值 1.00 元，每股发行价格为人民币 11.03 元， 募集资金总额为人民币 750,481,200.00 元，扣除相关发行费用 12,948,580.21 元 （不含税）后，本次非公开发行实际募集资金净额为人民币 737,532,619.79 元。 2022 年 12 月 5 日，希格玛会计师 ...

独立董事述职报告（相征） 2023 年度，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 二、独立董事年度履职概况 （一）参加股东大会和出席董事会会议情况 2023 年度任职期间，公司共召开了 9 次董事会会议，本人均按时出席会议， 没有缺席或连续两次未亲自出席会议的情况。2023 年度任职期间，本人共参加 1 次股东大会。本着勤勉尽责的原则，本人认真审核了提交董事会的所有议案，主 动了解公司经营情况，并与公司管理层进行了充分的沟通，获取相关信息，以审 慎态度行使表决权，本人认为公司董事会的召集召开符合法定程序，重大经营事 项均履行了相关审批程序，因此，对董事会各项议案均投了赞成票，无提出异议 的事项，没有反对和弃权的情形。 西安环球印务股份有限公司 独立董事 2023 年度述职报告 各位股东及股东代表： 本人作为西安环球印务股份有限公司（以下简称"公司"）的独立董事，在 根据《公司法》、《上市公司独立董事管理办法》、《上市公司独立董事履职指 引》、《上市公司治理准则》、《公司章程》、《公司独立董事工作制度》及有 关法律法规的规定和要求，认真履行职责，充分发挥独立董 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥539,587,507.41, a decrease of 20.29% compared to ¥676,970,746.02 in the same period last year[4]. - The net profit attributable to shareholders for Q1 2022 was ¥27,402,907.36, down 8.77% from ¥30,036,045.48 in the previous year[4]. - The basic earnings per share for Q1 2022 was ¥0.11, a decrease of 8.33% from ¥0.12 in the same period last year[5]. - The net profit for Q1 2022 was CNY 31,925,678.59, a decrease of 12.5% compared to CNY 36,354,428.69 in Q1 2021[23]. - The operating profit for Q1 2022 was CNY 35,695,830.95, down from CNY 42,192,555.84 in the same period last year, reflecting a decline of 15.5%[23]. - The total comprehensive income for Q1 2022 was CNY 31,925,678.59, down from CNY 36,354,428.69 in the same period last year, reflecting a decrease of 12.5%[24]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥25,807,505.26, compared to a negative cash flow of ¥52,731,812.25 in the same period last year, representing a 148.94% increase[4]. - The total revenue from sales and services received in cash was CNY 647,469,986.06, compared to CNY 691,175,879.11 in the previous year, indicating a decline of 6.3%[27]. - The company reported a total cash outflow from financing activities of CNY 265,719,478.39, compared to CNY 188,911,308.03 in the previous year, indicating an increase of 40.6%[28]. - Cash and cash equivalents at the end of Q1 2022 were CNY 233,565,112.62, down from CNY 274,281,873.94 at the end of Q1 2021[28]. - The cash and cash equivalents decreased to CNY 253,874,088.24 from CNY 299,361,975.03 at the beginning of the year[18]. Assets and Liabilities - The total assets at the end of Q1 2022 were ¥1,627,394,738.32, a slight decrease of 0.62% from ¥1,637,617,535.07 at the end of the previous year[5]. - The total liabilities as of March 31, 2022, were CNY 750,940,418.22, down from CNY 793,088,893.48 at the start of the year[20]. - The company's non-current liabilities decreased to CNY 46,212,111.38 from CNY 52,048,370.07 at the beginning of the year[20]. - The equity attributable to shareholders increased by 3.61% to ¥785,800,449.03 from ¥758,397,541.67 at the end of the previous year[5]. - The company's retained earnings increased to CNY 446,548,767.31 from CNY 419,145,859.95 at the beginning of the year[20]. Operational Developments - The company is expanding its production capacity with a new green packaging intelligent manufacturing industrial park project in Xi'an, which includes a primary and secondary pharmaceutical packaging production center and a technology R&D center[13]. - The company has signed a construction project general contracting contract with China Construction Fourth Engineering Bureau for the new industrial park[13]. - The company has strengthened its collection of accounts receivable, contributing to the improved cash flow from operating activities despite a decline in revenue[8]. Research and Development - Research and development expenses amounted to CNY 16,502,638.89, a decrease of 32.1% from CNY 24,341,072.20 in Q1 2021[23]. Share Issuance - The company plans to issue up to 68,040,000 shares through a non-public offering, which will not exceed 27% of the total share capital before the issuance[14]. - The company received approval from the China Securities Regulatory Commission for the non-public offering on March 2, 2022[14].

证券代码：002799 证券简称：环球印务 公告编号：2024-022 西安环球印务股份有限公司 关于2024年度公司为控股子公司提供担保额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《证券法》、《公司法》和《深圳证券交易所股票上市规则》的有关规 定，西安环球印务股份有限公司（以下简称"公司"、"环球印务"、"本公 司"）于 2024 年 4 月 25 日召开了第六届董事会第三次会议、第六届监事会第三 次会议，审议通过《关于 2024 年度公司为控股子公司提供担保额度的议案》， 现将有关事项公告如下： 一、担保情况概述 为保证公司子公司天津滨海环球印务有限公司（以下简称"天津环球"）、霍 尔果斯领凯网络科技有限公司及其控股子公司（以下简称"领凯科技及其控股子 公司"）、北京金印联国际供应链管理有限公司及其控股子公司（以下简称"金印 联及其控股子公司"）、西安凌峰环球印务科技有限公司（以下简称"凌峰环球"） 的正常生产、经营需要，公司对 2024 年度子公司拟向金融机构申请授信额度 5 亿元、向合作供应商申请赊销额度 1.12 亿元事项提供担保 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,600,910,936, a decrease of 17.07% compared to CNY 1,930,489,320 in 2022[21] - The net profit attributable to shareholders of the listed company was CNY 221,928,603, representing a decline of 356.29% from CNY 106,357,144 in the previous year[21] - Basic and diluted earnings per share were both CNY -0.69, a decrease of 302.94% from CNY 0.36 in 2022[21] - The weighted average return on net assets was -15.11%, down from 11.22% in the previous year[21] - Total assets decreased by 17.62% to CNY 2,599,701,360 from CNY 2,604,514,570[22] - Net profit attributable to shareholders decreased by 14.42% to CNY 1,582,517,660 from CNY 1,586,106,870[22] - The company reported a total operating cost of ¥1,356,209,316, which is a reduction of 17.86% year-over-year[79] - The company reported a significant increase of 343.20% in construction in progress to 414,839,786, mainly for subsidiary projects and equipment purchases[98] Cash Flow and Investments - The net cash flow from operating activities increased significantly to CNY 134,527,227, a rise of 593.24% compared to CNY 27,273,965 in 2022[21] - The company reported a net cash flow from operating activities of CNY -10,698,900.14, compared to CNY 78,092,342.92 in the previous year[28] - Investment cash inflow surged by 12,514.84% to ¥1,452,899.26, primarily due to received dividend payments[91] - Investment cash outflow increased by 219.89% to ¥310,144,484.02, mainly due to engineering expenses paid by subsidiaries[92] - The net increase in cash and cash equivalents was negative at -¥351,293,488.63, a decline of 157.48% compared to the previous year[91] - The company has committed to invest a total of 73,753 million CNY in various projects, with 49,023 million CNY already utilized by the end of the reporting period[111] Research and Development - The company has maintained its commitment to research and development, focusing on new product innovations and technology advancements[21] - The company is focusing on high-efficiency automation, low-carbon green development, and digital intelligence in its R&D efforts[84] - The company has completed multiple anti-counterfeiting technology developments, with some products already applying these technologies in mass production[85] - R&D investment decreased by 26.17% to ¥47,046,363.74, accounting for 2.94% of operating revenue[88] - The number of R&D personnel decreased by 19.05% to 153, with a proportion of 14.81%[88] Market Strategy and Expansion - The company is exploring market expansion opportunities to enhance its competitive position[21] - The company aims to expand its market presence in the fast-moving consumer goods packaging sector, targeting medical devices, health care products, and cosmetics[85] - The company is focusing on developing new products such as low-odor coatings and antibacterial coatings to enhance market competitiveness[88] - The company plans to expand its production capacity and implement smart manufacturing projects to achieve digital and intelligent upgrades, ensuring growth in pharmaceutical and consumer goods packaging[130] - The company is committed to exploring new forms of internet digital marketing, investing in commercial data and technology product development to strengthen its competitive advantage[132] Risk Management - The company has outlined potential risks in its future development outlook, urging investors to be cautious[4] - The company faces risks from national policy adjustments affecting the pharmaceutical and consumer goods packaging industries, which could impact its operational status[140] - The company acknowledges the risk of intensified competition in the pharmaceutical and consumer goods packaging sectors, which may affect its future strategic development[141] - The company is aware of the risks associated with raw material price fluctuations and is implementing strategies to manage supply chain costs effectively[148] Corporate Governance and Management - The company experienced a leadership change with the resignation of the chairman Li Yiling due to reaching the legal retirement age on January 10, 2023[178] - The company appointed a new general manager, Xia Shunwei, on August 28, 2023, following the resignation of Sun Xuejun[180] - The board of directors will undergo a re-election process on January 4, 2024, to ensure effective corporate governance[179] - The company has implemented a performance-based salary system for its directors and senior management, linking remuneration to annual operating performance and personal assessments[195] Environmental Commitment - The company is committed to green production and smart manufacturing, investing in environmental protection and digital transformation of production equipment[46] - The company has maintained a B-level environmental performance rating in Shaanxi Province and has upgraded its waste gas treatment equipment, enhancing its competitive advantage in environmental protection[50] Client and Market Relationships - The company has established long-term partnerships with major pharmaceutical firms, including several Fortune 500 companies, ensuring a stable growth trajectory in the pharmaceutical packaging sector[44] - The company serves over 800 clients across various industries, including e-commerce, gaming, education, finance, and internet, continuously improving its marketing service capabilities and data analysis[53] - The company has successfully collaborated with high-quality clients such as Betaini, Giant Bio, and L'Oreal, enhancing its market presence[126]

证券代码：002799 证券简称：环球印务 公告编号：2024-013 一、行政监管措施决定书的主要内容 西安环球印务股份有限公司、李移岭、雷永泉、孙学军、林蔚： 经查，你公司 2022 年、2023 年定期报告和季度报告存在以下信息披露不准确的问 题： 1、部分业务收入确认方法不符合会计准则规定 你公司下属子公司霍尔果斯领凯网络科技有限公司（以下简称领凯科技）开展的互 联网数字营销业务，在走量、收量业务模式中，业务交易实质为广告代充值业务，领凯 科技既不负责广告的制作、投放，也不对广告投放效果负责，在向客户转让商品或服务 前无法拥有对该商品或服务的控制权，在该类业务模式中领凯科技的身份是代理人，应 当按照净额法确认相关收入。你公司对该类业务采用总额法核算，不符合《企业会计准 则第 14 号—收入》(2017 年修订）第三十四条有关规定，导致你公司 2022 年、2023 年 定期报告和季度报告中收入相关信息披露不准确。 2、部分应收账款坏账准备计提不充分，相关款项回收风险揭示不到位 截至 2022 年末，领凯科技对北京头脑风暴科技有限公司（以下简称头脑风暴）的 应收账款余额为 2.46 亿元，至审计报告出具 ...

证券代码：002799 证券简称：环球印务 公告编号：2024-012 西安环球印务股份有限公司 经中国证券监督管理委员会《关于核准西安环球印务股份有限公司非公开发 行股票的批复》（证监许可〔2022〕397 号）核准，公司向特定对象非公开发行人 民币普通股 68,040,000 股，每股面值 1.00 元，每股发行价格为人民币 11.03 元， 募集资金总额为人民币 750,481,200.00 元，扣除相关发行费用 12,948,580.21 元（不含税）后，本次非公开发行实际募集资金净额为人民币 737,532,619.79 元。2022 年 12 月 5 日，希格玛会计师事务所（特殊普通合伙）对本次募集资金 到位情况进行了审验，出具了《西安环球印务股份有限公司验资报告》（希会验 字(2022)0060 号）。 为规范公司募集资金管理和使用，保护投资者权益，公司设立了相关募集资 金专项账户。募集资金到账后，已全部存放于募集资金专项账户内，并与保荐机 构、存放募集资金的商业银行签署了募集资金三方、四方监管协议。 二、募集资金投资项目情况 （一）募集资金使用计划及使用情况 公司本次非公开发行股票募集资金扣除 ...